# Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

> **NCT00479388** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1216 (actual)

## Conditions studied

- Primary Hypercholesterolemia
- Mixed Dyslipidemia

## Interventions

- **DRUG:** Comparator: simvastatin
- **DRUG:** niacin (+) laropiprant
- **DRUG:** Comparator: atorvastatin calcium

## Key facts

- **NCT ID:** NCT00479388
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-07
- **Final completion:** 2008-10
- **Target enrollment:** 1216 (ACTUAL)
- **Last updated:** 2015-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00479388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00479388, "Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00479388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*